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.2013.09Abstract Prokinetic drugs are used for the management of gastrointestinal motility disorders in
horses; however, little is known about their efﬁcacy in donkeys. Therefore, the aim of the present
study was to evaluate the effect of different doses of mosapride citrate on duodenal and cecal motil-
ity in normal donkeys. Six donkeys (n= 6) were used in a crossover study. Mosapride citrate was
administered orally via a nasogastric tube at dose rate of 1, 2 and 3 mg kg1. Duodenal and cecal
motility were evaluated using ultrasonography before administration and at 15, 30, 60, 120 and
180 min post-administration. There was a signiﬁcant increase of duodenal contractions
(p< 0.05) after 30 min of mosapride citrate administration at 3 mg kg1 with a prolonged
(p< 0.05) prokinetic effect at 2 mg kg1. Cecal contractions were signiﬁcantly increased
(p< 0.05) after 15 min at different doses of mosapride with a prolonged effect at 3 mg kg1. The
results of the present study indicate that mosapride citrate has a dose-dependent prokinetic effect; GI, gastro-intestinal; 5-HT4,
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52 N.A. Gomaa et al.on the duodenal and cecal contractions in healthy donkeys. Further studies need to determine
whether mosapride citrate is effective in treatment of intestinal disorders in donkey.
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University.1. Introduction
Gastrointestinal motility disorders are common in donkeys
and result in colic. The main disorders are intestinal impaction
and typhlocolitis [1–3]. Impaction colic represents 50% of the
colic episodes in donkeys with incidence rate of 3.9 per100
donkeys per year [4]. The impaction was diagnosed in all parts
of the intestine, but the majority of impactions (51%) occurred
in the pelvic ﬂexure [5]. The recovery rate in donkeys with
impaction colic was approximately 49% [4].
Prokinetic drugs are commonly used for management of
Post-operative ileus (POI) in horses [6]. Generally, prokinetic
agents increase the release or availability of acetylcholine from
cholinergic pathways (e.g., neostigmine), enhance activity at
dopamine-1 and 5-hydroxytryptamine 4 (5-HT4) receptors
and antagonize inhibitory neurotransmitters (e.g., metoclopra-
mide), or simulate non-cholinergic non-adrenergic molecules
that promote contractile activity (e.g., erythromycin) [7].
The recently developed GI prokinetic agent (mosapride
citrate) is a substituted benzamide that acts as a selective
5-HT4 agonist; thereby it is increasing neuronal release of
acetylcholine from nerve endings in the digestive tract and pro-
moting GI motility including small intestine and caecum of
experimental animals and horses [8,9] . Mosapride citrate has
been demonstrated to promote jejunal and cecal motility in
normal horses without adverse effects compared with other
prokinetic agents [10,11].
At the moment, only limited information is available about
intestinal motility disorders in donkeys. Ultrasonographic
examination is a valuable non-invasive method for evaluating
intestinal motility in horses [12–15]. Therefore, the purpose of
the present study was to evaluate the effect of different doses of
mosapride citrate on the duodenal and cecal motility in don-
keys using ultrasonography.
2. Materials and methods
2.1. Study overview and animals
Six adult healthy donkeys (Equus asinus), (4 geldings and 2
mares) were used in a crossover study. The age of donkeys ran-
ged from 9 to 17 years and body weight from 100 to 220 kg.
None of those donkeys had gastrointestinal disorders or evi-
dence of systemic diseases. Two weeks before starting the
study, each donkey was stabled on straw-bedded boxes and
fed twice a day with 1 kg hay/100 kg B.W. and 0.5 kg concen-
trate with unlimited access to water. This study was carried out
at Department of Animal Medicine, Faculty of Veterinary
Medicine, Kafr El-sheikh University, Egypt. These trials were
approved by Animal Welfare and Ethics Committee, Faculty
of Veterinary Medicine, Kafr Elsheikh University.2.2. Protocol of the study
Each donkey underwent four trials with one week interval be-
tween each trial and the consecutive one. Each trail was started
one hour after feeding. Intestinal contractions at descending
duodenum and body of cecum were counted via ultrasonogra-
phy. The ﬁrst trial was carried out by oral administration of
1000 ml of clean water via a nasogastric tube (control group).
Second, third and fourth trials were conducted by oral
administration of mosapride citrate (Gasmotin powder ,
Dainippon Pharmaceutical Co., Ltd., Japan) dissolved in
1000 ml of water at dose rates of 1, 2 and 3 mg kg1 respec-
tively (treated groups). The intestinal contractions were
counted over a period of 3 min before treatment and at 15,
30, 60, 120 and 180 min post-treatment. During the monitoring
periods, there was no access to food or water. Evidence of any
adverse effects as behavioral abnormalities was also monitored
following the administration of mosapride citrate.
2.3. Ultrasonographic examination
Transcutaneous ultrasonographic examinations were per-
formed with a 5 MHz curved-linear transducer (CHISON Dig-
ital Color Doppler Ultrasound system, iVis 60 EXPERT VET,
CHISON Medical Imaging Co., Ltd.). The donkeys were re-
strained in stocks without any sedation during ultrasono-
graphic examinations. The position of the descending
duodenum and cecal body in each donkey was identiﬁed be-
fore the beginning of ultrasonographic examinations. The
descending duodenum was located at the right thoracic area
extending from the 8th to the 18th rib along the line joining
the olecranon and tuber coxae. The cecal body was identiﬁed
in the upper part of the right para-lumbar region. The abdo-
men was clipped at those identiﬁed regions, cleaned with alco-
hol and then coupling gel was applied to enhance the contact
with the probe.
Intestinal contractions per three min were counted via ultr-
asonographic examination according to Freeman [13], Mitch-
ell et al. [14] and Gomaa et al. [15]. One hour after feeding,
ultrasonographic examinations and counting of segmental
contractions were carried out at 9:00 AM by the same person
to avoid any individual variations and revised again by two
persons to overcome the lack of randomization and blindness
during drug administration.
2.4. Statistical analyses
Data analyses were performed using a statistical software pro-
gram (SPSS for windows Version 16, SPSS Inc., Chicago,
USA). Data were tested for normal distribution using Kolmo-
grov-Smirnov test. The data were normally distributed; there-
Fig. 2 Ultrasonographic picture of descending duodenum in a
donkey during segemental contraction phase. (C) right dorsal
colon; (L) liver; (Arrow) duodenum which appears a round shape.
Dose-dependent effects of mosapride citrate 53fore, mean and standard deviation for each assessed treatment
at each time point was calculated. ANOVA (with repeated mea-
sures on dose and time) were used to determine the main effect
of dose and time. Wilks’ Lambda test indicated a statistically
signiﬁcant difference between groups. One way ANOVA with
Turkey post-hoc multiple comparison tests was used to identify
which group was statistically different from the rest. Differ-
ences between means at p< 0.05 were considered signiﬁcant.
3. Results
The descending duodenum was constantly observed at 12th–
13th intercostal space. During ultrasonographic examination,
descending duodenum was visualized between the liver and
the right dorsal colon as an oval to round shape (Figs. 1 and
2). Only the segmental contractions of descending duodenum
were counted.
The cecal body´s wall appeared as a mobile hypoechoic line
overlying a hyperechoic gas shadow adjacent to the right
abdominal wall by ultrasonographic examination (Fig. 3). In
the cecum, the normal motility comprised either localized seg-
mental contractions (mixing) or propagating (propulsive)
motility in both forward and backward directions during ultr-
asonographic examination. The cecal contractions were
counted by visualizing the movement of cecal body away from
abdominal wall (Fig. 4).
The duodenal and cecal body contractions before treatments
were 6.9 ± 1.3 and 4.0 ± 0.8 contractions/3 min, respectively.
Furthermore, administration of clean water did not exert a sig-
niﬁcant effect on both duodenal and cecal body contractions.
Mosapride citrate showed a dose-dependent effect on duo-
denal contractions (Wilks, Lambda test for time effect,
p< 0.05; Wilks, Lambda test for time x dose interaction,
p< 0.05). At a dose rate of 3 mg kg1 the duodenal contrac-
tions were increased signiﬁcantly after 30 min post-administra-
tion compared with control (13.7 ± 4.8 vs 8.3 ± 1.8
contractions/3 min). At 120 min. post-administration, doses
of 2 and 3 mg kg1 were signiﬁcantly higher than control.
However, at 180 min, only 2 mg kg1 showed a signiﬁcant in-
crease compared with control (Fig. 5).Fig. 1 Ultrasonographic picture of descening duodenum in a
donkey during relaxation phase. (C) right dorsal colon; (L) liver;
(Arrow) duodenum which appears an oval shape.
Fig. 3 Ultrasonographic picture of cecum in a donkey. It
appears adjacent to body wall at the most upper part of picture.
The cecal wall (B) appears hyperechoic line from multiple
refrection, and acoustic shadow (A) from gas in cecum.A dose-dependent effect of mosapride citrate on cecal
motility was also recorded (Wilks, Lambda test for time effect,
p< 0.05; Wilks, Lambda test for time x dose interaction,
p< 0.05). Cecal motility increased after 15 min post-adminis-
tration at 1, 2 and 3 mg kg1 (4.3 ± 0.5, 6.5 ± 1.4, 6.0 ± 1.3
contractions/3 min, respectively). Only at a dose rate of
3 mg kg1, the motility still has a signiﬁcant increase at
120 min post-administration (Fig. 6).
Regarding to adverse effect, no behavioral abnormalities or
other adverse reactions was observed in treated donkeys at dif-
ferent dose rates.
4. Discussion
Prokinetic drugs are usually used for management of POI in
horses after small intestinal injury but less commonly used
for large intestinal disorders [6]. In donkeys, although large
Fig. 4 Ultrasonographic picture of cecum during mixing con-
traction. The cecal body wall (B) moves away the abdominal wall
about 2 cm which representing the mixing contraction. An
acoustic shadow (A) from has in cecum.
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rence of other motility disorders cannot be ruled out. The pres-
ent study was constructed to evaluate the duodenal and cecal
motility in donkeys and to assess the prokinetic effect of differ-
ent doses of mosapride citrate. For this purpose, transcutane-
ous abdominal ultrasonography was used.
Duodenum and cecum could be easily visualized because
they are a relatively superﬁcially located adjacent to the
abdominal wall. This result is in concurrent with previous re-
ports in horses and ponies [12,15,16]. Before treatment, the fre-
quency of duodenal and cecal contractions in donkeys was
6.9 ± 1.3 and 4.0 ± 0.8 contractions/3 min, which are closely
similar those in horses [14,15,17] It appears that donkeys may
have decreased duodenal contractions than ponies [16]. Varia-
tions in duodenal and cecal contractions among members ofFig. 5 Duodenal contractions (number/3 min) in donkeys afterequidae were attributed to time of ultrasonographic examina-
tion, feeding practice and diet composition [16]. Our ultraso-
nographic ﬁndings in donkeys are in agreement with
previous studies, which highlight the importance of ultrasound
as non-invasive technique for examination of gastrointestinal
tract in equines [13,18]. On the contrary, electrointestinogra-
phy (EIG) has been found superior to ultrasonography to as-
sess the intestinal motility, because EIG can be performed
continuously for 24 h, and can determine intestinal smooth
muscle contractility more objectively [19].
In this study, mosapride citrate provided a dose-dependent
effect on duodenal contraction (p< 0.05). The effect started at
30 min post-administration, and persisted until 3 h. Other
studies reported an increase in gastric emptying in horses after
30 min of oral administration of 1 mg kg1 of mosapride cit-
rate [9,20] and also a signiﬁcant increase in small intestinal
motility after 120 min at 2 mg/kg of mosapride citrate [11].
This could be attributed to the effect of mosapride as substi-
tuted benzamide selective 5-HT4 agonist on the motility of
GI tract [21,22].
5-HT4 receptors are abundantly distributed along the GI
tract and modulate smooth muscle tone, peristaltic reﬂex and
mucosal secretion [23,24]. Mosapride selectively acts on
5-HT4 receptors and increases the level of acetylcholine
released from cholinergic nerve endings in the digestive tract
[7,9,24]. Acetylcholine binds to muscarinic receptors on the
smooth muscle and stimulates the contractions [25,26].
Another mode of action of mosapride citrate is based on the
pharmacological effect of mosapride on gastrointestinal func-
tion, which is closely related to changes in motilin immunoac-
tive substance level in plasma. In human, the peak of plasma
motilin level is achieved 60 min after oral administration of a
single dose of mosapride, and returns to base line level within
120 min [27].
Based on the pharmacokinetics of oral mosapride in horses,
the maximum concentration of mosapride (Cmaxs) in plasma is
a dose dependent. The Cmaxs reaches the highest level at a dose
rate of 1.5 mg kg1. However, the time to peak serum concen-
tration (tmax) and apparent serum elimination half-life (t1/2)
reach the highest level at a dose rate of 0.5 mg kg1 [28]. Sim-
ilar to the present result, a dose-dependent effect of mosaprideoral administration of different doses of mosapride citrate.
Fig. 6 Cecal contractions (number/3 min) in donkeys after oral administration of different doses of mosapride citrate.
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age range of 0.03–3.0 mg kg1 [7].
Actually, the pharmacokinetic proﬁle of mosapride citrate
is quite different from human to animal and from animal to
another [29]. It depends mainly on the ﬁrst pass effect of mosa-
pride or its bio-availability or metabolism. It is suggested that
mosapride undergoes less ﬁrst pass effect in horse [28] than in
dog and monkey [30], but higher than human [31]. The maxi-
mum serum levels of the mosapride reach 1–2 h after oral
administration in horses [28]. It is also suggested that half-life
(t1/2) of mosapride in horses is 2 folds longer than in healthy
man. This criterion is attributed to low metabolism of mosa-
pride citrate in horses compared with human [28,32]. In the
present study, although the prokinetic effect of oral mosapride
citrate is closely similar to those reported in horses, complete
pharmacokinetic proﬁle of mosapride citrate in donkeys is
needed to have more accurate conclusion.
In this study, mosapride citrate showed a dose-dependent
(p< 0.05) prokinetic effect on cecal motility in donkeys at 2
and 3 mg kg1 which started after 15 min of oral administra-
tion. This conﬂicted with other previous studies on horses that
reported an increase of cecal motility after 180 to 300 min at
2 mg kg1 of mosapride administration [20]. This could be
attributed to difference of mosapride metabolism in donkeys
from horses. The rapid effect of mosapride citrate on cecal
motility rather than on duodenum could be attributed to the
activation of muscarinic receptors, which are more concen-
trated in cecum and colon [33]. Previous studies suggested that
neither intravenous nor oral administration of 1 mg kg1 of
mosapride citrate was effective in the lower region of gastroin-
testinal tract in dogs [22,34]. However, other reports concluded
that mosapride could improve colonic motility at 3 mg kg1 in
rat and at 2 mg kg1 in horse [20,34].
According to this study, the administration of mosapride
citrate at 2 mg kg1 has a similar effect to 3 mg kg1 on duo-
denum and cecal contractions. Therefore, 2 mg kg1 is consid-
ered to be sufﬁcient to promote the duodenal and cecal
motility in donkey. However, it was recorded that mosapride
citrate has a prolonged effect on duodenal and cecal contrac-
tions at 2 and 3 mg kg-1 respectively. This enhancement of co-
lonic motility as well as duodenal motility may lead toimprovement of constipation with dysfunction of the lower
GI motility [21].
Interestingly, mosapride citrate showed no adverse effect in
experimental donkeys. Similar ﬁndings have been reported in
horses [20] and human [35]. In dogs, oral administration of
mosapride citrate at 3 mg kg1 could alter the electrocardio-
graphic parameters by increasing the heart rate, shortening
QT interval and prolongation of the QTc [36]. Cisapride may
also trigger tachycardia and supraventricular dysrhythmia
through stimulation of 5-HT4 atrial receptors [37].
The present investigation was constructed as a crossover
study, which doesn’t allow for randomization of the order
for mosapride and water administration. Water was adminis-
tered ﬁrst to prevent residual effects of mosapride during the
water administration period. The other limitations of present
study are lack of information about the pharmacokinetic of
mosapride citrate in donkeys and failure to assess the propul-
sive contractions of the duodenum and cecum. Therefore,
avoidance of these limitations in further studies is warranted.
In conclusion, mosapride citrate showed dose-dependent ef-
fects on small intestinal and cecal motility in conscious don-
keys without any adverse effects. Mosapride at 2 mg kg1
seems to be the most effective prokinetic dose, which promotes
duodenal and cecal contraction. However, 3 mg kg1 is more
efﬁcient on cecal contractions. These ﬁndings could be unprac-
tical in donkeys with GIT dysfunction. Therefore, further stud-
ies on the effect of mosapride citrate in donkeys with ileus or
cecal impaction are needed.References
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